Actinium Pharmaceuticals, Inc.
(NYSE Amex Equities : ATNM)

( )
ATNM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.17%203.561.3%$427.08m
BIIBBiogen Inc.
-0.93%225.601.3%$388.53m
GILDGilead Sciences, Inc.
-0.35%65.000.9%$366.13m
CELGCelgene Corporation
0.82%101.801.3%$356.32m
ILMNIllumina, Inc.
0.28%310.553.5%$253.40m
REGNRegeneron Pharmaceuticals, Inc.
0.73%301.572.6%$219.86m
EXASExact Sciences Corporation
-0.20%97.3924.1%$203.99m
ALXNAlexion Pharmaceuticals, Inc.
0.48%99.992.0%$181.39m
VRTXVertex Pharmaceuticals Incorporated
0.93%177.721.9%$178.93m
AAgilent Technologies, Inc.
-0.47%74.921.6%$143.96m
SRPTSarepta Therapeutics, Inc.
0.81%87.4414.6%$138.15m
BMRNBioMarin Pharmaceutical Inc.
-0.06%67.904.3%$95.86m
SGENSeattle Genetics, Inc.
2.48%85.946.2%$90.55m
NKTRNektar Therapeutics
1.31%17.775.5%$84.92m
ALDRAlder Biopharmaceuticals, Inc.
0.16%18.9010.2%$83.36m

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.